Eli Lilly has communicated the acquisition of Calytrix Bio, a biotechnology company focused on the development of treatments for patients with myeloproliferative neoplasms, a type of blood cancer. The transaction is valued at $1.5 billion (€1.36 billion).
The financial agreement includes an initial payment supplemented with additional payments conditioned on the achievement of certain clinical and regulatory milestones. In the transaction, Centerview Partners acts as exclusive financial advisor to Calytrix, while Goodwin Procter provides legal counsel to the biotechnology company. On the part of Lilly, the law firm Paul, Weiss, Rifkind, Wharton & Garrison serves as legal advisor.
The lead candidate of Calytrix is designed to provide disease-modifying activity, with a safety and comfort profile that facilitates early intervention and prolonged treatment over time.
The pharmacological treatments currently available for certain hematological conditions are aimed above all at managing symptoms and complications, leaving room for precision therapies specifically directed at the mutations that cause the disease.
Calytrix was incorporated in 2025, driven by JPMorgan Life Sciences Private Capital, the venture capital arm specialized in life sciences of JPMorgan Asset Management. The company began its journey with a Series A funding round co-chaired by JP Morgan Life Sciences Private Capital and Westlake BioPartners, followed by a Series B round led by Avoro Ventures.
"Calytrix was founded with the conviction that patients with myeloproliferative neoplasms deserve therapies that go beyond the mere control of symptoms," Calytrix Bio’s president and chief executive officer Brad Prosek has said.
"This transaction represents an important step toward accelerating that vision. We expect Lilly to advance the program through clinical trials and explore its potential to benefit patients across the spectrum of the disease. I am deeply grateful to our team, scientific advisors, and committed investors, who have supported the development of the Calytrix program up to its launch in the clinical setting," he added.